



PATENT
ATTORNEY DOCKET NO.: 044137-5025-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Alan SOLOMON *et al.*

U.S. Application No.: 09/316,387

Filed: May 21, 1999

FOR: METHODS FOR AMYLOID REMOVAL
USING ANTI-AMYLOID ANTIBODIES

)
)
)
)
) Group Art Unit: 1647
)
) Examiner: Sharon L. Turner
)
)
)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop RCE**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. patents and published U.S. applications, a copy of each listed document is attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP


Date: March 16, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
SPT:mk

By:


Sally P. Teng, Ph.D.
Registration No. 45,397
Tel. No.: (202) 739-5734
Fax No.: (202) 739-3001

FORM PTO-1449 (modified). To: U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 044137-5025-01		Client Ref.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: Alan Solomon <i>et al.</i>			
				Appln. No.: 09/316,387			
				Filed: May 21, 1999			
				Examiner: Sharon Turner		Group Art Unit: 1647	
Date: March 16, 2005							
U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	
	4,666,829 A	05/1987	Glenner <i>et al.</i>				
	4,713,366 A	12/1987	Stevens				
	5,004,697 A	04/1991	Pardridge				
	5,057,540 A	10/1991	Kensil <i>et al.</i>				
	5,187,153 A	02/1993	Cordell <i>et al.</i>				
	5,192,753 A	03/1993	McGeer, <i>et al.</i>				
	5,208,036 A	05/1993	Eppstein <i>et al.</i>				
	5,220,013 A	06/1993	Ponte <i>et al.</i>				
	5,231,000 A	07/1993	Majocho <i>et al.</i>				
	5,231,170 A	07/1993	Averback				
	5,270,165 A	12/1993	Van Nostrand <i>et al.</i>				
	5,387,742 A	02/1995	Cordell				
	5,434,170 A	07/1995	Andrulis, Jr.				
	5,441,870 A	08/1995	Seubert <i>et al.</i>				
	5,464,823 A	11/1995	Lehrer <i>et al.</i>				
	5,571,499 A	11/1996	Hafler <i>et al.</i>				
	5,571,500 A	11/1996	Hafler <i>et al.</i>				
	5,583,112 A	12/1996	Kensil <i>et al.</i>				
	5,585,100 A	12/1996	Mond <i>et al.</i>				
	5,593,846 A	01/1997	Schenk <i>et al.</i>				
	5,605,811 A	02/1997	Seubert <i>et al.</i>				
	5,612,486 A	03/1997	McConlogue <i>et al.</i>				
	5,622,701 A	04/1997	Berg				
	5,641,473 A	06/1997	Haffler <i>et al.</i>				
	5,641,474 A	06/1997	Hafler <i>et al.</i>				
	5,645,820 A	07/1997	Haffler <i>et al.</i>				
	5,679,348 A	10/1997	Nesburn <i>et al.</i>				
	5,688,651 A	11/1997	Solomon				
	5,721,130 A	02/1998	Seubert <i>et al.</i>				
	5,733,547 A	03/1998	Weiner <i>et al.</i>				
	5,736,142 A	04/1998	Sette <i>et al.</i>				
Examiner				Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							


FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.	Client Ref.
	044137-5025-01	
	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
Date: March 16, 2005	Examiner: Sharon Turner	Group Art Unit: 1647



U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	5,744,368 A	04/1998	Goldgaber <i>et al.</i>			
	5,750,349 A	05/1998	Suzuki <i>et al.</i>			
	5,750,361 A	05/1998	Prusiner <i>et al.</i>			
	5,753,624 A	05/1998	McMichael <i>et al.</i>			
	5,776,468 A	07/1998	Hauser <i>et al.</i>			
	5,780,587 A	07/1998	Potter			
	5,786,180 A	07/1998	Konig <i>et al.</i>			
	5,824,322 A	10/1998	Balasubramanian			
	5,837,473 A	11/1998	Maggio <i>et al.</i>			
	5,837,672 A	11/1998	Schenk <i>et al.</i>			
	5,846,533 A	12/1998	Prusiner			
	5,849,298 A	12/1998	Weiner <i>et al.</i>			
	5,851,996 A	12/1998	Kline			
	5,854,204 A	12/1998	Findeis <i>et al.</i>			
	5,869,054 A	02/1999	Weiner <i>et al.</i>			
	5,869,093 A	02/1999	Weiner <i>et al.</i>			
	5,877,399 A	03/1999	Hsiao <i>et al.</i>			
	5,935,927 A	08/1999	Vitek <i>et al.</i>			
	5,955,079 A	09/1999	Mond <i>et al.</i>			
	5,955,317 A	09/1999	Suzuki <i>et al.</i>			
	5,958,883 A	09/1999	Snow			
	5,989,566 A	11/1999	Cobb <i>et al.</i>			
	6,057,367 A	05/2000	Stamler <i>et al.</i>			
	6,114,133 A	09/2000	Seubert <i>et al.</i>			
	6,150,091 A	11/2000	Pandolfo <i>et al.</i>			
	6,262,335 B1	07/2001	Hsiao <i>et al.</i>			
	6,284,221 B1	09/2001	Schenk <i>et al.</i>			
	6,284,533 B1	09/2001	Thomas			
	6,294,171 B2	09/2001	McMichael			
	6,399,314 B1	06/2002	Krishnamurthy			
	6,417,178 B1	07/2002	Klunk <i>et al.</i>			

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 044137-5025-01	Client Ref. <div style="text-align: center;">  </div>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
	Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005		

U.S. PATENT DOCUMENTS


Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	2001/0018053 A1	08/2001	McMichael			
	2001/0021769 A1	09/2001	Prusiner			
	2002/0009445 A1	01/2002	Du <i>et al.</i>			
	2002/0077288 A1	06/2002	Frangione			
	2002/0086847 A1	07/2002	Chain			
	2002/0094335 A1	07/2002	Chalifour <i>et al.</i>			
	2002/0102261 A1	08/2002	Raso			
	2002/0132268 A1	09/2002	Chang <i>et al.</i>			
	2002/0133001 A1	09/2002	Gefler <i>et al.</i>			
	2002/0136718 A1	09/2002	Raso			
	2002/0160394 A1	10/2002	Wu			
	2002/0162129 A1	10/2002	Lannfelt			
	2002/0168377 A1	11/2002	Schaetzl			
	2002/0187157 A1	12/2002	Jensen <i>et al.</i>			
	2002/0197258 A1	12/2002	Ghanbari <i>et al.</i>			
	2003/0068325 A1	04/2003	Wang			
	2003/0073655 A1	04/2003	Chain			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
	0 276 723 B1	12/1993	EP	Muller-Hill <i>et al.</i>				
	0 359 783 B2	11/1995	EP	Weiner <i>et al.</i>				
	0 440 619 B1	01/1996	EP	Majocha <i>et al.</i>				
	0 451 700 A1	10/1991	EP	Wirak <i>et al.</i>				
	0 506 785 B1	03/2000	EP	Hafler <i>et al.</i>				
	0 526 511 B1	05/1997	EP	Kline <i>et al.</i>				
	0 526 611 B1	05/1997	EP	Lylykangas <i>et al.</i>				
	0561 087 B1	08/1999	EP	Van Broeckhoven <i>et al.</i>				
	0 594 607 B1	08/1997	EP	Weiner <i>et al.</i>				
	0 613 007 A2	08/1994	EP	Becker <i>et al.</i>				
	0 639 081 B1	11/1999	EP	Roberts <i>et al.</i>				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.	Client Ref.
	044137-5025-01	
	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
Date: March 16, 2005	Examiner: Sharon Turner	Group Art Unit: 1647



FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Enclosed	No	Enclosed	No
		0 652 962 B1	12/1998	EP	Khan <i>et al.</i>				
		0 666 080 B1	08/1995	EP	Weiner <i>et al.</i>				
		0 683 234 A1	11/1995	EP	Suzuki <i>et al.</i>				
		0 782 859 A1	07/1997	EP	Weiner <i>et al.</i>				
		0 783 104 A1	07/1997	EP	Taniguchi <i>et al.</i>				
		0 845 270 A1	06/1998	EP	Matsuda				
		0 863 211 A1	09/1998	EP	Khan <i>et al.</i>				
		0 868 918 B1	10/1998	EP	Momin <i>et al.</i>				
		0 911 035 A2	04/1999	EP	Brader				
		0 911 036 A2	04/1999	EP	Mond <i>et al.</i>				
		1 172 378 A1	01/2002	EP	Dodel <i>et al.</i>				
		2 220 211 A	01/1990	GB	Myers <i>et al.</i>				
		2 335 192 A	09/1999	GB	Hoffer				
		88/10120	12/1988	WO	Weiner <i>et al.</i>				
		89/01343	02/1989	WO	Pardridge <i>et al.</i>				
		89/03687	05/1989	WO	Brown				
		89/06242	07/1989	WO	Majocha <i>et al.</i>				
		89/06689	07/1989	WO	Marotta				
		90/12870	11/1990	WO	Kim <i>et al.</i>				
		90/12871	11/1990	WO	Kim <i>et al.</i>				
		91/08760	06/1991	WO	Hafler <i>et al.</i>				
		91/12816	09/1991	WO	Autoimmune, Inc. & Brigham and Women's Hospital				
		91/16819	12/1991	WO	Treutner <i>et al.</i>				
		91/19810	12/1991	WO	Cordell				
		92/06187	04/1992	WO	Greenberg				
		92/06708	04/1992	WO	Weiner <i>et al.</i>				
		92/13069	08/1992	WO	Hardy <i>et al.</i>				
		92/13089	08/1992	WO	Hoseloff <i>et al.</i>				
		93/02189	02/1993	WO	Neve				
		93/04194	03/1993	WO	Maggio <i>et al.</i>				
		93/14200	07/1993	WO	Wadsworth <i>et al.</i>				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Client Ref.

044137-5025-01

Applicant: Alan Solomon *et al.*

Appln. No.: 09/316,387


Filed: May 21, 1999

Examiner: Sharon Turner

Group Art Unit: 1647

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: March 16, 2005



FOREIGN PATENT DOCUMENTS


		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
		93/15760	08/1993	WO	Mond <i>et al.</i>				
		93/16724	09/1993	WO	Weiner <i>et al.</i>				
		93/21950	11/1993	WO	Roberts <i>et al.</i>				
		94/01772	01/1994	WO	Yankner				
		94/03615	02/1994	WO	Khan <i>et al.</i>				
		94/03815	02/1994	WO	Ratcliffe				
		94/28412	12/1994	WO	Marotta <i>et al.</i>				
		95/04151	02/1995	WO	Khan <i>et al.</i>				
		95/05853	03/1995	WO	Carson <i>et al.</i>				
		95/11008	04/1995	WO	Cleland <i>et al.</i>				
		95/11311	04/1995	WO	Strittmatter <i>et al.</i>				
		95/11994	05/1995	WO	Seubert <i>et al.</i>				
		95/12815	05/1995	WO	Goldgaber <i>et al.</i>				
		95/31996	11/1995	WO	Kline <i>et al.</i>				
		96/18900	06/1996	WO	Solomon				
		96/25435	08/1996	WO	Konig <i>et al.</i>				
		96/28471	09/1996	WO	Findeis <i>et al.</i>				
		96/39176 A1	12/1996	WO	Chen <i>et al.</i>				
		97/10505 A1	03/1997	WO	Prusiner <i>et al.</i>				
		97/17613 A1	05/1997	WO	O'Mahony				
		97/21728 A1	06/1997	WO	Nordstedt <i>et al.</i>				
		98/07850 A2	02/1998	WO	Bergmann <i>et al.</i>				
		98/44955 A1	10/1998	WO	Chain				
		99/00150 A2	01/1999	WO	Pardridge				
		99/06066 A2	02/1999	WO	Trasciatti <i>et al.</i>				
		99/06545 A2	02/1999	WO	Wanker <i>et al.</i>				
		99/27911 A1	06/1999	WO	Yoshida <i>et al.</i>	X			
		99/27944 A1	06/1999	WO	Schenk				
		99/27949 A1	06/1999	WO	Weiner <i>et al.</i>				
		99/58554 A1	11/1999	WO	Kishishita <i>et al.</i>	X			
		99/58564 A1	11/1999	WO	Gaudernack <i>et al.</i>				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.	Client Ref.
	044137-5025-01	
	Applicant: Alan Solomon <i>et al.</i>	
	Appl. No.: 09/316,387	
	Filed: May 21, 1999	
Date: March 16, 2005	Examiner: Sharon Turner	Group Art Unit: 1647




FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Enclosed	No	Enclosed	No
		99/60021 A2	11/1999	WO	Eisenbach-Schwartz <i>et al.</i>				
		99/60024 A1	11/1999	WO	Solomon <i>et al.</i>				
		00/43039 A1	07/2000	WO	During				
		00/43049 A1	07/2000	WO	Mallory <i>et al.</i>				
		00/72870 A1	12/2000	WO	Hirtzer <i>et al.</i>				
		00/72876 A2 A3	12/2000	WO	Schenk				
		00/72878 A1	12/2000	WO	Rimstad				
		00/72880 A2	12/2000	WO	Schenk <i>et al.</i>				
		00/77178 A1	12/2000	WO	Raso				
		01/39796 A2	06/2001	WO	Chalifour <i>et al.</i>				
		01/42306 A2	06/2001	WO	Chain				
		01/42308 A2	06/2001	WO	Barbas <i>et al.</i>				
		01/62264 A2	08/2000	WO	Zawadzki <i>et al.</i>				
		01/62284 A2	08/2001	WO	Birk <i>et al.</i>				
		01/62601 A1	08/2001	WO	Sichera <i>et al.</i>				
		01/62801 A2	08/2001	WO	Holtzman <i>et al.</i>				
		01/77167 A2	10/2001	WO	Solomon <i>et al.</i>				
		01/90182 A2	11/2001	WO	Frangione <i>et al.</i>				
		02/03911 A2	04/2001	WO	Näslund <i>et al.</i>				
		02/34777 A1	05/2002	WO	Ghirardi <i>et al.</i>				
		02/34878 A2	05/2002	WO	Groner <i>et al.</i>				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
		Andersen <i>et al.</i> , Neurology, Vol. 45, August, 1995, 1441-1445							
		The Boston Globe, "Immune cells may promote Alzheimer's, a study finds", Associated Press, April 17, 1994, Wednesday AM cycle							
		Bauer <i>et al.</i> , Federation of European Biochemical Societies, Vol. 285, No. 1, 111-114							
		Blass, The New England Journal of Medicine, November 25, 1999, 1694-1695							
		Bodmer <i>et al.</i> , Biochemical and Biophysical Research Communications, Vol. 171, No. 2, Sept. 14, 1990, 890-897							
		Borchelt <i>et al.</i> , Neuron, Vol. 19, October, 1997, 939-945							
		Boris-Lawrie <i>et al.</i> , Current Opinion in Genetics and Development, 1993, 3:102-109							

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 044137-5025-01	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
	Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005		




OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				
	Moll <i>et al.</i> , Journal of Neurology, Neurosurgery, and Psychiatry, 1993; 56:112-115			
	Chao <i>et al.</i> , Abstract No. 513.7, Society for Neuroscience, Abstracts, Vol. 19, Part 2, Nov. 1993,			
	Duff <i>et al.</i> , Nature, Vol. 373, Feb. 9, 1995, 476-477			
	Elizan <i>et al.</i> , Journal of Neurological Sciences, 1983, 59: 341-347			
	Felsenstein <i>et al.</i> , Neuroscience Letters, 1993, 152: 185-189			
	Finch <i>et al.</i> , Neurobiol. Aging, 1996, 17(5): 809-815			
	Fisher <i>et al.</i> , Proc. Natl. Acad. Sci. USA., Vol. 88, pp. 1779-1782, March 1991			
	Flanders <i>et al.</i> , Neurology, 1995, 45:1561-1569			
	Gandy <i>et al.</i> , Tips, March 1992, Vol. 13, pp. 108-113			
	Gaskin <i>et al.</i> , J. Exp. Med. Vol. 177, April 1993, 1181-1186			
	Glenn <i>et al.</i> , Nature, Vol. 391, 26 Feb. 1998, pp. 851			
	Glenner <i>et al.</i> , Biochemical and Biophysical Research Communications, Vol. 120, No. 3, May 16, 1984, pp. 885-890			
	Glenner <i>et al.</i> , Biochemical and Biophysical Research Communications, Vol. 122, No. 3, August 16, 1984, pp. 1131-1135			
	Goate <i>et al.</i> , Nature, Vol. 349, 21 Feb. 1991, 704-706			
	Gozes <i>et al.</i> , Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 427-432, January 1996			
	Gupta <i>et al.</i> , Vaccine, Vol. 15, 12/13, pp. 1341-1343, 1997			
	Haga <i>et al.</i> , Brain Research, 601 (1993) 88-94			
	Hanes <i>et al.</i> , Advanced Drug Delivery Reviews, 28 (1997) 97-119			
	Hardy, TINS, Vol. 20, No. 4, 1997, 154-159			
	Hardy, The Finnish Medical Society DUODECIM, Ann Med 28, 255-258, 1996			
	Hsiao <i>et al.</i> , Science, Vol. 274, 4 October 1996, 99-102			
	Shalit <i>et al.</i> , Journal of Neuroimmunology, 52 (1994) 147-152			
	Hyman <i>et al.</i> , The New England Journal of Medicine, Vol. 33, No. 19, 1283-1284, Nov. 9, 1995			
	Itagaki <i>et al.</i> , Journal of Neuroimmunology, 24 (1989) 173-182			
	Jansen <i>et al.</i> , Immunological Rev. (1982) Vol. 62, 185-216			
	Kalaria, Research in Immunology, 1992, 143:637-641			
	Kawabata, Nature, Vol. 354, 12 December 1991, 476-478			
	Lampert-Etchells <i>et al.</i> , Neurodegeneration, Vol. 2, pp. 111-121 (1993)			


Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449*(modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 044137-5025-01	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alan Solomon <i>et al.</i>	
		Appln. No.: 09/316,387	
		Filed: May 21, 1999	
		Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005			
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)			
	Langer, Science, Vol. 249, 28 September 1990, 1527-1533		
	Lannfelt <i>et al.</i> , Behavioral Brain Research, 57 (1993) 207-213		
	Lemere <i>et al.</i> , Abstract No. 519.6, Soc. for Neurosciences Abstracts, Vol. 25, Parts 1 & 2, 29th Annual Mtg., Oct. 23-28, 1999		
	Livingston <i>et al.</i> , The Journal of Immunology, 1997, 1383-1392		
	Rabin, Acta Neurol Scand 1991: 84: 441-444		
	McGee <i>et al.</i> , J. Microencapsulation, 1997. Vol. 14, No. 2, 197-210		
	Meda <i>et al.</i> , Nature, Vol. 374, 13 April 1995, 647-650		
	Miller <i>et al.</i> , J. Exp. Med., Vol. 174, October 1991, 791-798		
	Nathanson <i>et al.</i> , American Journal of Epidemiology, Vol. 145, No. 11, 1997, 959-969		
	The New York Times, "Anti-Inflammatory Drugs May Impede Alzheimer's", Feb. 20, 1994		
	Paresce <i>et al.</i> , Neuron, Vol. 17, 553-565, September 1996		
	Paul <i>et al.</i> , Eur. J. Immunol. 1995, 25:3521-3524		
	Prieela <i>et al.</i> , Abstract No. 120:86406t, Chemical Abstracts, ACS, Vol. 120, 1994, 652		
	Quon <i>et al.</i> , Nature, Vol. 352, 18 July 1991, 239-241		
	Raso, Grant Application No.: I B43 AGI5746-01		
	Raso, Immunotherapy Weekly, Abstract, April 2, 1998		
	Rogers <i>et al.</i> , Proc. Natl. Acad. Sci. USA., Vol. 89 (1992) 1-5		
	Rossor <i>et al.</i> , Annals of the New York Academy of Sciences. Vol. 695, 1993, 198-202		
	Schenk <i>et al.</i> , Nature, Vol. 400, 8 July 1999, 173-177		
	Games <i>et al.</i> , Letters to Nature, Vol. 373 - February 9, 1995, 523-527		
	Selkoe, Imaging Alzheimer's Amyloid, Nature Biotechnology, Vol 18, August 2000, 823- 824		
	Selkoe, Journal Of Neuropathology And Experiments, Vol. 53, No. 5, September, 1994, pp. 438-447		
	Selkoe, Trends In Neurosciences, Vol. 16, No. 10, October 1993, 409-414		
	Selkoe, Scientific American, November 1991, 68-75		
	Selkoe, Nature, Vol. 354, December 12, 1991, 432-433		
	Selkoe, Neuron, Vol. 6, April 1991, 487-498		
	Bard, <i>et al.</i> , Nature Medicine, Vol. 6, No. 8, August 2000, 916-919		
Examiner		Date Considered:	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 044137-5025-01	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alan Solomon <i>et al.</i>	
		Appln. No.: 09/316,387	
		Filed: May 21, 1999	
		Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005			




OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
	Helmuth, Science, Vol. 289, July 21, 2000, 375				
	Schenk, <i>et al.</i> , Journal Of Medicinal Chemistry, Vol. 38, Number 21, October 13, 1995, 4141-4154				
	Southwick, <i>et al.</i> , Journal Of Neurochemistry, Vol. 66, No. 1, 1996, 259-265				
	Wen, Journal Of Food And Drug Analysis, 1998, 6(2): 465-476				
	Hanan, <i>et al.</i> , Amyloid: Int. J. Exp. Clin. Invest. 3, 130-133 (1996)				
	Katzav-Gozansky, <i>et al.</i> , Biotechnol. Appl. Biochem., (1996) 23,, 227-230				
	Li, <i>et al.</i> , Biochemistry And Molecular Biology International, Vol. 43, No. 3, October, 1997, 601-611				
	Beka Solomon, <i>et al.</i> , Advances In Molecular And Cell Biology, Vol. 15A, 1996, 33-45				
	Beka Solomon, <i>et al.</i> , Activity Of Monoclonal Antibodies In Prevention Of In Vitro Aggregation Of Their Antigens, Abstract, 305 (publication date unknown)				
	Saido, <i>et al.</i> , The Journal Of Biological Chemistry, Vol. No. 33, November 25, 1993, 25239-25243				
	Gravina, <i>et al.</i> , The American Society For Biochemistry And Molecular Biology, Inc., Vol. 270, No. 13, March 31, 1995, 7013- 7016				
	Murphy, <i>et al.</i> , American Journal Of Pathology, Vol. 144, No. 5, May 1994, 1082-1088				
	Iwatsubo, <i>et al.</i> , Neuron, Vol 13, July 1994, 45-53				
	Harrington, <i>et al.</i> , Biochem. Biophysica Acta, 1158(1993) 120-128				
	Saido, <i>et al.</i> , The Journal Of Biological Chemistry, 69, No. 21, Issue Of May 27, 1994, 15253-15257				
	G. König, <i>et al.</i> , Annals New York Academy Of Sciences, Vol. 777, January, 1996, 344-355				
	Bercovici, <i>et al.</i> , Eur. J. Immunol. (1999), 29:345-354				
	Mori, <i>et al.</i> , The Journal Of Biological Chemistry, Vol. 267, No. 24, August 25, 1992, 17082-17086				
	J.A. Parsons, Peptide Hormones, June 1976, J. Rudinger, Characteristics Of The Amino Acids As Components Of A Peptide Hormone Sequencein Peptide Hormones, 1-7, edited by Parsons, J.A., <i>et al.</i> , 1976				
	Friedland, <i>et al.</i> , Molecular Neurobiology, Vol. 9, 1994, 107-113				


Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 044137-5025-01		Client Ref. 	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alan Solomon <i>et al.</i>			
		Appln. No.: 09/316,387			
		Filed: May 21, 1999			
		Examiner: Sharon Turner		Group Art Unit: 1647	
Date: March 16, 2005					
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
		Selkoe, SCIENCE, Vol. 275, January 31, 1997, 630-631			
		Seubert, <i>et al.</i> , Nature – Vol. 359, September 24, 1992, 325-327			
		Shiosaka, Neuroscience Research, 13 (1992), 237-255			
		Smits, <i>et al.</i> , The Veterinary Quarterly, Vol. 19, No. 3, September 1997, 101-105			
		Solomon, <i>et al.</i> Proc. Natl. Acad. Sci. USA, April 1997, Vol. 94, 4109-4112,			
		Solomon, <i>et al.</i> , Proc. Natl. Acad. Sci. USA, January 1996, Vol. 93, 452-455			
		Solomon, Pro-Rx (Protein Therapeutics) and Pro-Dx, (Protein Diagnostics) (publication date unknown, University of Tennessee Medical Center			
		Solomon, New Approach Towards Fast Induction Of Anti β -Amyloid Peptide Immune Response, Dept. of Mol. Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown)			
		Stoute, <i>et al.</i> , The New England Journal Of Medicine, January 9, 1997, 86-91			
		Christine Sturchler-Pierrat, <i>et al.</i> , Proc. Natl. Acad. Sci. USA, November 1997 – Vol. 94, 13287-13292			
		Tanaka, <i>et al.</i> , European Journal Of Pharmacology 352 (1998), 135-142			
		Trieb, <i>et al.</i> , Immunobiology, Vol. 191, No. 2-3, 1994, 114-115			
		Van Gool, <i>et al.</i> , Neuroscience Letters 172 (1994) 122-124			
		Werbeek, <i>et al.</i> , AJP January 1994, Vol. 144, No. 1, 104-116			
		Walker, <i>et al.</i> , Journal Of Neuropathology And Experimental Neurology, July, 1994, Vol. 53, No. 4, 377-383			
		Wengenack, <i>et al.</i> , Nature Biotechnology, August 2000, Vol. 18, 868-872			
		Weiner, <i>et al.</i> , Annual Rev. Immunol. 1994, 809-837			
		Weissmann, <i>et al.</i> , Current Opinion in Neurobiology 1997, 7:695-700			
		Johnson-Wood, <i>et al.</i> , Proc. Natl. Acad. Sci. USA, February 1997, 94, 1550-1555			
		Human Immunology And Cancer Program, The University Of Tennessee Medical Center/Graduate School Of Medicine, Knoxville (publication date unknown)			
		Sette, <i>et al.</i> , Disclaimer, Alteration Of Immune Response Using Pan Dr-Binding Peptides, Official Gazette, July 29, 1999, 1 page			
		Bickel, <i>et al.</i> , Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid As A Potential Diagnostic Imaging Technique For Alzheimer's Disease, Society For Neuroscience, Abstracts (325.6) Vol. 18, 1992, 764			
		Chen, <i>et al.</i> , Neuroscience Letters, 125:223-226 (1991)			
Examiner		Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					




FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 044137-5025-01		Client Ref.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alan Solomon <i>et al.</i>			
		Appln. No.: 09/316,387			
		Filed: May 21, 1999			
		Examiner: Sharon Turner		Group Art Unit: 1647	
Date: March 16, 2005					
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
		Demattos, <i>et al.</i> Proc. Natl. Acad. Sci., www.pnas.org/cgi/dgl/10.1073/pnas.151261398 (2001)			
		Games, <i>et al.</i> , Annals New York Academy Of Sciences, 920:274-284 (2000)			
		Joachim, <i>et al.</i> , American Journal Of Pathology, Vol. 138, No. 2, February 1991, 373-384			
		Masters, <i>et al.</i> , Proc. Natl. Acad. Sci USA, Vol. 82, June 1985, 4245-4249			
		Majocha, <i>et al.</i> , The Journal Of Nuclear Medicine, Vol. 33, No. 12, December 1992, 2184-2189			
		Wong, <i>et al.</i> , Proc. Natl. Acad. Sci. USA 82 (1985) 8729-8732			
		Diaglog/Derwent Abstract, WPI Acc No.: 1997-054436/199706			
		Chem Abstract Database, 1971:417711			
		Wisconsin Alumni Research Foundation, Final Report, Contract No. Ph 43-67-684, June 19, 1969, 1-130			
		CBER, U.S.F.D.A., Thimerosal In Vaccines, http://www.fda.gov/cber/vaccine/thimerosal.htm, May 28, 2002			
		Elan: News, Elan and AHP Provide An Update On The Phase 2A Clinical Trial Of AN-1792, January 18, 2002			
		Elan: News, Elan and Syeth provide update on status of Alzheimer's collaboration, March 1, 2002			
		Borrow, <i>et al.</i> , J. Mol. Biol. (1992) 225, 1075-1093			
		Hazama, <i>et al.</i> , Immunology, 1993, 78, 643-649			
		Peterson, Laboratory Of Animal Science, Vol. 46, No. 1, February 1996, 8-14			
		Morris, <i>et al.</i> , Neurology, September 1969, 39, 1159-1165			
		Newcombe, <i>et al.</i> , Biochemica et Biophysica Acta. 104 (1963) 480-486			
		Hilbich, <i>et al.</i> , Eur. J. Biochem. 201, 61-69 (1991)			
		Gortner, <i>et al.</i> , Outlines Of Biochemistry, Third Edition, 322-323, John Wiley & Sons, Inc. New York, 1999			
		McNeal, <i>et al.</i> , Virology, 243, 158-166 (1998)			
		Deena Beasley, Alzheimer's Traced To Proteins Caused By Aging, Reuters, The New York Times, April 20, 2001			
		Haass, <i>et al.</i> , Nature, Vol. 359, September 24, 1992, 322-325			
		Frenkel <i>et al.</i> , Journal of Neuroimmunology, 106 (2000) 23-31			
		Frenkel, <i>et al.</i> , Journal Of Neuroimmunology 95 (1999) 136-142			
Examiner		Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					



FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 044137-5025-01		Client Ref. 	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alan Solomon <i>et al.</i>			
		Appln. No.: 09/316,387			
		Filed: May 21, 1999			
		Examiner: Sharon Turner		Group Art Unit: 1647	
Date: March 16, 2005					
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
		Frenkel <i>et al.</i> , Vaccine, 19 (2001), 2615-2619			
		Frenkel, <i>et al.</i> , PNAS, 2000, Vol. 97, No. 21, 11455-11459			
		Frenkel, <i>et al.</i> , Journal of Neuroimmunology 88 (1998) 85-90			
		Friedland, <i>et al.</i> , Annals New York Academy Of Sciences, 1997, 242-247			
		Nakamura, <i>et al.</i> , Exp. Anim. 43(5), 711-718, 1995			
		Gardella, <i>et al.</i> , Biochemical And Biophysical Research Communications, Vol. 173, No. 3, 1990, 1292-1298			
		Geddes, <i>et al.</i> , Neurobiology Of Aging, 20 (1999) 75-79			
		Giulian, <i>et al.</i> , The Journal Of Biological Chemistry, Vol. 273, No. 45, November 6, 1998, 29719-29726			
		Grubeck-Loebenstien, <i>et al.</i> , TINS Vol. 23, No. 3, 2000, 114			
		Harigaya, <i>et al.</i> , Biochemical And Biophysical Research Communications, Vol. 211, No. 3, 1995, June 26, 1995, 1015-1022			
		Ikeda, <i>et al.</i> , Laboratory Investigation, 1987, Vol. 57 No. 4, 446-449			
		Jen, <i>et al.</i> , Brain Research Protocols, 2 (1997) 23-30			
		Kida, <i>et al.</i> , Neuroscience Letters, 193 (1995) 105-108			
		Peter T. Lansbury, Jr., Current Opinion in Chemical Biology, 1997, 260-267			
		Lemere, <i>et al.</i> , Annals New York Academy Of Sciences, 920, 328-331 (2001)			
		Mak, <i>et al.</i> , Brain Research, 667 (1994) 138-142			
		Mann, <i>et al.</i> , Neuroscience Letters, 196 (1995) 105-108			
		Mann, <i>et al.</i> , Annals Of Neurology, Vol. 40, No. 2, August 1996, 149-156			
		McGeer, <i>et al.</i> , Journal Of Neuroscience Research, 31: 428-442 (1992)			
		Mena, <i>et al.</i> , Acta Neuropathol (1995) 89:50-56			
		Paul F. Chapman, Nature, Vol. 408, 21/28 December 2000, 915-916			
		Nakamura, <i>et al.</i> , Neuroscience Letters, 201(1995) 151-154			
		Philippe, <i>et al.</i> , Journal Of Neuroscience Research 46:709-719 (1996)			
		Schenk, <i>et al.</i> , Arch Neurol, Vol. 57, July 2000, 934-936			
		St. George-Hyslop, <i>et al.</i> , Nature, Vol. 400, July 8, 1999, 116-117			
		Szendrei, <i>et al.</i> , International Journal Peptide Protein Research, 47, 1996, 289-296			
Examiner		Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					




FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 044137-5025-01	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
	Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005		




OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				
Thorsett, <i>et al.</i> , Current Opinion in Chemical Biology, 2000, 4, 377-382				
Weiner, <i>et al.</i> , Annals Of Neurology, Vol. 48, No. 4, October 2000, 567-579				
Wu, <i>et al.</i> , J. Clin. Invest. Vol. 100, No. 7, October 1997, 1804-1812				
Tjernberg, <i>et al.</i> , The Journal Of Biological Chemistry, Vol. 271, No. 15, April 12, 8545-8548, 1996				
Sasaki, <i>et al.</i> , Brain Research, 755 (1997) 193-201				
Saitoh, <i>et al.</i> , Immunological Analysis Of Alzheimer's Disease Using Anti- β -Protein Monoclonal Antibodies, 60 (3) 309-320 (1991)				
Saito, <i>et al.</i> , Proc. Natl. Acad. Sci USA, Vol. 92, October 1995, 10227-10231				
Pardridge, <i>et al.</i> , Biochemical And Biophysical Research Communications, Vol. 146, No. 1, 1987, July 15, 1987, 307-313				
Nakamura, <i>et al.</i> , Journal Of Medical Primatology, 1998, 27:244-252				
Caputo, <i>et al.</i> , Clin. Neuropharm, Vol 15, Suppl. 1, Pt. A., 1992, 414A-415A				
Cordell, Annu. Rev. Pharmacol. Toxicol. 1994, 34: 69				
Costa, <i>et al.</i> , Scand. J. Immunol. 38, 177-182, 1993				
Dumery, <i>et al.</i> , Pathol Biol, 2001: 49: 72-85				
Margaret M. Esiri, Trends In Pharmacological Sciences, Vol. 22 No. 1, January 2001, 2-3				
Steven J. Younkin, Nature Medicine, Vol. 7, Number 1, January 2001, 18-19				
Coloma, <i>et al.</i> , Pharmaceutical Research, Vol. 17, No. 3, 2000, 266-274				
Yamaguchi, <i>et al.</i> , Acta Neuropathol (1998) 95: 217-222				
Daly IV, <i>et al.</i> , Life Sciences, 1998, Vol. 63, No. 23. 2121-2131				
Chung, <i>et al.</i> , The Journal Of Biological Chemistry, Vol. 274, No. 45, November 5, 1999, 32301-32308				
Gonzalez-Fernandez, <i>et al.</i> , Immunology, 1998, 93, 149-153				
Raso, Immunotherapy Of Alzheimer's Disease, Grant Application No: 1 R43 AG15746-01 (publication date unknown)				
Chen, <i>et al.</i> , Nature, Vol. 408, December 2000, 975-979				
Janus, <i>et al.</i> , Nature, Vol. 408, December 2000, 979-982				
Mark P. Mattson, Physiological Reviews, Vol. 77, No. 4, October 1997, 1081-1132				
Meduzzi, <i>et al.</i> , Advances In Clinical Pathology, 2004, 4, 77-85				
Morgan, <i>et al.</i> , Nature, Vol. 408, December 2000, 983-985				
Schenk, <i>et al.</i> , DNA And Cell Biology, Vol. 20, Number 11, 2001, 679-681				
Selkoe, Trends In Cell Biology Vol. 8, November 1998, 447-453				
Sigurdsson, <i>et al.</i> , Journal Of Neuropathology And Experimental Neurology, Vol. 59, No. 1, January, 2000, 11-17				

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 044137-5025-01	Client Ref. <div style="text-align: center;">  </div>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
	Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005		
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)		
	Sinha, <i>et al.</i> , Annals New York Academy Of Sciences, 920:206-208 (2000)	
	Soto, <i>et al.</i> , Nat. Med. 4(7), 822-826, 1998	
	Vehmas, <i>et al.</i> , DNA And Cell Biology, Vol. 20, Number 11, 2001, 713-721	
	Du, <i>et al.</i> , Neurology, 57, September (1 of 2) 2001, 801-805	
	Small, <i>et al.</i> , Nat. Rev. Neuroscience, Vol. 2, (8):595-598 (2001)	
	Cameron, Molecular Biotechnology, Vol. 7, 1997, 253-265	
	Felsenstein, <i>et al.</i> , Alzheimer's and Parkinson's Diseases, 401-409, 1995	
	Neiman, Transgenic Research 7, 73-75 (1998)	
	Curt D. Sigmund, Arterioscler Thromb Vasc Biol, June 2000, 1425-1429	
	Chen, <i>et al.</i> , Progress In Brain Research, Vol. 117, 327-334 (1998)	
	Conway, <i>et al.</i> , Proc. Natl. Acad. Sci., January 18, 2000, Vol. 97, No. 2, 571-576	
	Jobling, <i>et al.</i> , Molecular Microbiology (1991) (7), 1755-1767	
	Masliah, <i>et al.</i> , PNAS, October 9, 2001, Vol. 98, No. 21, 12245-12250	
	Perutz, <i>et al.</i> , PNAS, April 16, 2002, Vol. 99, No. 8, 5591-5595	
	Skolnick, <i>et al.</i> , Trends in Biotech, 18(1), 34-39, 2000	
	Stein, <i>et al.</i> , The Journal Of Neuroscience, September 1, 2002, 22(17): 7380-7388	
	Tennent, <i>et al.</i> , Proc. Natl. Acad. Sci. USA, Vol. 92, May 1995, 4299-4303	
	Jorbeck, <i>et al.</i> , Infection And Immunity, May 1981, 497-502	
	Erica Check, Nature, Vol. 422, March 27, 2003, 370-372	
	Nicoll, <i>et al.</i> , Nature Medicine, Vol. 9, Number 4, April 2003, 448-452	
	Ernst Mutschler, <i>et al.</i> , Drug Actions – Basic Principles And Therapeutic Aspects, , Scientific Publishers, 1995, pp. 7, 11, 12	
	Paul L. Munson, Principles Of Pharmacology – Basic Concepts & Clinical Applications, Chapman & Hall, 1995, pp. 47-48	
	Münch, <i>et al.</i> , J. Neural Transm (2002) 109: 1081-1087	
	Su, <i>et al.</i> , Brain Research, 818(1) (1999) 105-117	
	Dodart, <i>et al.</i> , Trends In Molecular Medicine, Vol. 9, No. 3, March 2003, 85-87	
	Furlan, <i>et al.</i> , Brain (2003), 126, 285-291	
	Monsonogo, <i>et al.</i> , PNAS, August 28, 2001, Vol. 98, No. 18, 10273-10278	
	Jean D. Sipe, Ann. Rev. Biochem. 1992, 61: 947-975	
Examiner	Date Considered:	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		


FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.	Client Ref.
	044137-5025-01	
	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
Date: March 16, 2005	Examiner: Sharon Turner	Group Art Unit: 1647



OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
	Spooner, <i>et al.</i> , Vaccine, 21 (2002) 290-297				
	Johnstone, <i>et al.</i> , Biochemical and Biophysical Research Communications 220, 710-718 (1996)				
	Akiyama, <i>et al.</i> , GLIA, 25:324-331 (1999)				
	Jakes, <i>et al.</i> , Alzheimer Disease and Associated Disorders, 1995, Vol. 9, No. 1, 47-51				
	Tsuzuki, <i>et al.</i> , Neuroscience Letters 202 (1995) 77-80				
	Sigurdsson, <i>et al.</i> , American Journal Of Pathology, Vol 161, No. 1, July 2002, 13-17				
	Wisniewski, <i>et al.</i> , Biochemical Society Transactions, (2002) Vol. 30, Part 4, 574-578				
	Frautschy, <i>et al.</i> , Proc. Natl. Acad. Sci USA, Vol. 88, 8362-8366, October 1991				
	Weldon <i>et al.</i> , Society For Neuroscience Abstracts, Vol. 22, Part 1, No. 81.6				
	Goldfarb, <i>et al.</i> , Annu. Rev. Med. 1993, 46:57-65				
	Kovacs, <i>et al.</i> , J. Neurol (2002) 249: 1567-1582				
	Diomedea, <i>et al.</i> , Biochem. J. (1996) 320, 563-570				
	Aguizzi, <i>et al.</i> , Nature, Vol. 389, October, 1997, 795-798				
	Tal, <i>et al.</i> , Journal Of Neuroscience Research 71:286-290 (2003)				
	Akiyama, <i>et al.</i> , Neurobiology Of Aging, 21 (2000) 383-421				
	Prusiner, <i>et al.</i> , Proc. Natl. Acad. Sci. USA, Vol. 90, 10608-10612, November 1993				
	Sigurdsson, <i>et al.</i> , Neuroscience Letters 336 (2003) 185-187				
	Goldsteins, <i>et al.</i> , Proc. Natl. Acad. Sci. USA, Vol. 96 3108-3113, March 1999				
	Pahla, <i>et al.</i> , J. Mol. Med (2001) 78:703-707				
	Tan, <i>et al.</i> , Histopathology, 1994, 25. 403-414				
	Sigurdsson, <i>et al.</i> , Neurobiology Of Aging, 23 (2002) 1001-1008				
	Benjamini, <i>et al.</i> , Immunology A Short Course, 49-65, Wiley-Liss, Inc., 1991				
	Pan, <i>et al.</i> , β -Amyloid and the BBB, 2002, 609-615				
	Brugge, <i>et al.</i> , Neurology, 44, February 1994, 232-238				
	B.T. Hyman, Down Syndrome and Alzheimer Disease, 123-142, Wiley-Liss, Inc., 1992				
	Jelic, <i>et al.</i> , Acta Neurologica Scandinavica 2003: 107 (Suppl. 179): 83-93				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.	Client Ref.
	044137-5025-01	
	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
Date: March 16, 2005	Examiner: Sharon Turner	Group Art Unit: 1647



U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	6,838,592	01/2005	Nixon <i>et al.</i>			
	2003/0165496 A1	04/2003	Basi <i>et al.</i>			
	2004/0166119 A1	08/2004	Schenk			
	2004/0087777 A1	05/2004	Basi <i>et al.</i>			
	2004/0136993 A1	07/2004	Schenk <i>et al.</i>			
	2004/0146521 A1	07/2004	Schenk <i>et al.</i>			
	2004/0157779 A1	08/2004	Schenk			
	2004/0081657 A1	04/2004	Schenk			
	2004/0247591 A1	09/2004	Schenk <i>et al.</i>			
	2004/0170641 A1	09/2004	Schenk <i>et al.</i>			
	2004/0171815 A1	09/2004	Schenk <i>et al.</i>			
	2004/071816 A1	09/2004	Schenk <i>et al.</i>			
	2004/0175394 A1	09/2004	Schenk			
	2004/0219146 A1	11/2004	Schenk			
	2004/0228865 A1	11/2004	Schenk			
	2004/0247590 A1	11/2004	Schenk <i>et al.</i>			
	2004/0265308 A1	12/2004	Schenk <i>et al.</i>			
	2004/0265301 A1	12/2004	Schenk <i>et al.</i>			
	6,808,712 B2	10/2004	Schenk			
	6,787,637 B1	09/2004	Schenk			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
	2004/080419 A2	09/2004	WO	Basi <i>et al.</i>				
	2004/108895 A1	12/2004	WO	Basi <i>et al.</i>				


OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	Honda, <i>et al.</i> , Journal of Clinical Laboratory Analysis 12:172-178 (1998)			
	Mizuno, <i>et al.</i> , Biochemica et Biophysica Acta, 1373 (1998) 119-130			
	Suzuki, <i>et al.</i> , American Journal of Pathology, Vol. 145, No. 2, August 1994, 452-460			
	Suzuki, <i>et al.</i> , Science, Vol. 264, 27 May 1994, 1336-1340			

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 044137-5025-01	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Alan Solomon <i>et al.</i>	
	Appln. No.: 09/316,387	
	Filed: May 21, 1999	
	Examiner: Sharon Turner	Group Art Unit: 1647
Date: March 16, 2005		



U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	6,761,888	07/2004	Schenk <i>et al.</i>			
	6,170,226	03/2004	Schenk <i>et al.</i>			
	6,743,427	06/2004	Schenk <i>et al.</i>			
	6,750,324	06/2004	Schenk <i>et al.</i>			
	6,787,138 B1	09/2004	Schenk			
	6,787,139 B1	09/2004	Schenk			
	6,787,140 B1	09/2004	Schenk			
	6,787,143 B1	09/2004	Schenk			
	6,787,144 B1	09/2004	Schenk			
	6,787,523 B1	09/2004	Schenk			

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name		Enclosed	No	Enclosed	No
	94/17197	08/1994	WO	Suzuki <i>et al.</i>		X			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
	Yanagisawa, <i>et al.</i> , Neurobiology of Aging, 1998, Vol. 19, No. 15, 565-567							
	Gearing, <i>et al.</i> , Annals of Neurology, Vol. 39, No. 3, 1996, pp. 395-399							
	Wang, <i>et al.</i> , The Journal of Biological Chemistry, December 13, 1996, Vol. 271, No. 50, pp. 31894-31902							
	Su, <i>et al.</i> , Journal of Neuroscience Research, 53:177-186 (1998)							
	Li, <i>et al.</i> , Laboratory Investigation, 1998, Vol. 78, No. 4, pp. 461-469							
	Tekirian, <i>et al.</i> , Journal of Neuropathology and Experimental Neurology, Vol. 57, No. 1, January 1998, pp. 76-94							
	Kim, <i>et al.</i> , Neuroscience Research Communications Vol. 2, No. 3, 121-130, 1988							
	Liang, <i>et al.</i> , Biochemical and Biophysical Research Communications, 219, 962-967 (1996)							
	Bickel, <i>et al.</i> , "Bioconjugate Chem.", 1994, Vol. 5 (2): 119-125							
	Ida, <i>et al.</i> , The Journal of Biochemical Chemistry, Vol. 271, No. 37, Sept. 13, 1996, pp. 22908-22914							

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	